Pre-operative progesterone treatment confers survival benefit to node-positive breast cancer patients. Our recent study suggest progesterone acts through the down-regulation of its own receptor (PR) via increased expression of a non-coding microRNA miR-129-2, and through up-regulation of a novel signalling cascade to inhibit breast cancer cell invasion and migration. While several reports have documented role of long non-coding RNAs (lncRNAs) in breast cancer and hormonal therapy resistance, systemtic interrogation of their regulatory role in response to progesterone remains to be studied. Identification of these non-coding transcripts will provide better and deeper understanding of this disease using high throughput genomics and functional approaches.
